Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Unknown 3

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 150Colorectal Neoplasms 82Stomach Neoplasms 77Neoplasms 35Neoplasm Metastasis 35Pancreatic Neoplasms 25Triple Negative Breast Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 16Adenocarcinoma 13Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Biliary Tract Neoplasms 10Rectal Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma Of Esophagus 7Solid Tumor 6Ovarian Neoplasms 6Cholangiocarcinoma 6Nasopharyngeal Carcinoma 5Gastrointestinal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 4Nasopharyngeal Neoplasms 4Advanced Solid Tumors 4Sarcoma 3Melanoma 3Head and Neck Neoplasms 3

Interventions

pyrotinib 3Capecitabine 3Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × HER2 Positive Metastatic Breast Cancer × Capecitabine × Clear all
NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
279 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡